<DOC>
	<DOCNO>NCT00106639</DOCNO>
	<brief_summary>This Phase 2 study design evaluate safety efficacy 2 dose level CP-690,550 ( 15 mg twice daily 30 mg twice ) tacrolimus , combination basiliximab induction , mycophenolate mofetil corticosteroid , kidney transplant patient . Stage 1 randomize approximately 54 subject . After Stage 1 subject complete 6 month treatment , Stage 2 randomize additional 195 subject treatment group .</brief_summary>
	<brief_title>A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Recipient firsttime kidney transplant Between age 18 70 year , inclusive Recipient nonkidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>tofacitinib</keyword>
	<keyword>CP-690550</keyword>
	<keyword>kidney transplant</keyword>
</DOC>